# Nucleai

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nucleai

- Industry: Software
- Headquarters: Tel Aviv, Israel
- Website: www.nucleai.ai
- Total disclosed funding: $59M
- Latest round: Series B (Apr 3, 2024)
- Investors on record: 7

## About

Based in Tel Aviv, Israel, and founded in 2018 by Avi Veidman, Eliron Amir, and Lotan Chorev, Nucleai Inc. operates as a developer of artificial intelligence-based software solutions that use machine learning algorithms to detect cancer and gastrointestinal diseases in humans.  In April 2024, Nucleai Inc. raised USD 14 million in Series B funding led by Merck Ventures, with participation from returning investors Section 32, Sanofi Ventures, Debiopharm Innovation Fund, Fosun RZ Capital, Vertex Ventures Israel and Grove Ventures.

Nucleai focuses on AI-driven spatial biology technology to enhance precision medicine, improve drug development, and aid clinical treatment decisions. Their platform uses advanced geospatial AI methods to analyze cellular interactions in biopsies, translating data into actionable insights. This technology supports pharmaceutical companies in drug development and biomarker discovery, aiming to optimize therapeutic strategies and patient outcomes.

## Funding rounds

- Series B, Apr 3, 2024, $14M — Vertex Ventures Israel, M Ventures, Sanofi Ventures, Grove, Section 32, Fosun RZ Capital, Debiopharm Innovation Fund
- Series B, Mar 22, 2022, $33M — Vertex Ventures Israel, Sanofi Ventures, Grove, Section 32, Fosun RZ Capital, Debiopharm Innovation Fund
- Series A, Jul 7, 2020, $6.5M — Vertex Ventures Israel, Grove, Debiopharm Innovation Fund
- Seed, Mar 5, 2018, $5M — Vertex Ventures Israel, Grove

## Investors

- Vertex Ventures Israel (https://capitalatlas.ai/funds/vertex-ventures-israel) — Seed, Series A, Series B
- Grove (https://capitalatlas.ai/funds/grove) — Seed, Series A, Series B
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Series A, Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Fosun RZ Capital (https://capitalatlas.ai/funds/fosun-rz-capital) — Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series B